Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01808391
Other study ID # PROPEL version 3.0 - AEEI
Secondary ID
Status Completed
Phase N/A
First received March 4, 2013
Last updated January 26, 2017
Start date March 2013
Est. completion date April 2016

Study information

Verified date January 2017
Source Associations for Establishment of Evidence in Interventions
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a prospective, multicenter, historical controlled study. The present clinical study will measure non-inferiority of 12 month TLF rate compared to historical control.The selected historical control is the Xience V arm from RESOLUTE All-Comer clinical study, that study is a prospective, multicenter, randomized, two-arm, international, open-label study.The historical control did not have angiographic follow up before 12 months, in the present clinical study, only subjects with clinical follow-up conducted at 12 months without any pre-specified angiographic assessment prior to 12 month clinical follow-up will be part of this analysis cohort. Out of the total 1200 patients, 900 patients (clinical follow-up cohort) will be included in this analysis cohort.


Recruitment information / eligibility

Status Completed
Enrollment 1204
Est. completion date April 2016
Est. primary completion date May 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria:

- Patients aged 20 years or older.

- Patients with symptomatic coronary disease.

- Patients with a clinical indication for PCI and stenting of at least one coronary lesion, visually confirmed on coronary angiography.

- Patients who give informed consent to participate in this clinical study and sign the informed consent form approved by the institutional review board of each study site before the index PCI.

- Patients who agree to undergo all clinical follow-up procedures specified in the protocol for this clinical study.

- Patients in whom more than 50% occlusion or stenosis is visually confirmed in a native coronary artery with a diameter of 2.5 mm - 3.5 mm on coronary angiography and that has an anatomical structure suitable for PCI using Resolute Integrity zotarolimus-eluting stent.

Exclusion Criteria:

- Patients aged 85 years or older.

- Patients with cardiogenic shock.

- Patients who are pregnant or possibly pregnant.

- Patients who cannot comply with the antiplatelet therapy specified for this clinical study.

- Patients scheduled to undergo elective surgery within 6 months post-index PCI.

- Patients with a history of allergic reaction or hypersensitivity to zotarolimus, sirolimus, tacrolimus, everolimus, or other analogues or derivatives.

- Patients with an allergic reaction to antiplatelet or anticoagulant drugs, such as heparin, aspirin, ticlopidine, or clopidogrel, or contrast agents, or those who cannot tolerate these substances and to whom appropriate treatments cannot be given.

- Patients with hypersensitivity to cobalt, nickel, chrome, molybdenum, coated polymer (e.g., BioLinx) contained in the materials of the study device or in whom these substances are specifically contraindicated.

- Patients who are currently participating in a clinical study of another drug or medical device and in whom assessment of the primary endpoint of that study has not been completed or clinically interferes with the endpoints of this clinical study.

Study Design


Locations

Country Name City State
Japan Non-profit organization Associations for Establishment of Evidence in Interventions Minato-ku, Tokyo

Sponsors (2)

Lead Sponsor Collaborator
Associations for Establishment of Evidence in Interventions Medtronic Vascular

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Other Comparison of long-term clinical outcomes due to a difference in follow-up procedure (clinical follow-up or routine angiographic follow-up) after index PCI. 24 months after index PCI
Other Evaluation of medical economics The objectives of this clinical study are to 1) assess the efficacy and safety of RI-ZES at 10 and 22 months (±60 days) after index PCI for routine angiographic FU after index PCI and to 2) investigate its medical costs. 24 months after index PCI
Primary TLF (target lesion failure) The composite of Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel) or Target Lesion Revascularization (TLR; clinically indicated) (= device oriented endpoint). 12 months
Secondary Delivery success Complete passage of the stent across the target lesion with full expansion of the stent to the desired diameter at the desired location.
Note:
Failed delivery: failure to pass the stent through the guiding catheter into the coronary artery,failure to pass it completely across the target lesion, or failure to expand the stent to its desired diameter. Failed delivery includes proximal deployment defined as those instances of failed delivery when the stent could be advanced only partially across the target lesion but was deployed nonetheless by full expansion.
stent implantation until hospital discharge (average 1-5 days)
Secondary Lesion success Lesion success defined as the attainment of a less than 50% residual stenosis by any percutaneous method. stent implantation until hospital discharge (average 1-5 days)
Secondary TLF (target lesion failure) The composite of Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel) or Target Lesion Revascularization (TLR; clinically indicated) (= device oriented endpoint). 30 days, 6, 9, 12, 24 and 36 months after index PCI
Secondary TVF (target vessel failure) The composite of cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization by percutaneous or surgical methods. 30 days, 6, 9, 12, 24 and 36 months after index PCI
Secondary MACE (major adverse cardiac event) All-cause death, myocardial infarction (QWMI and NQWMI), emergency coronary artery bypass graft(CABG), or TLR by medical or surgical procedure. 30 days, 6, 9, 12, 24 and 36 months after index PCI
Secondary Stent thrombosis Incidence of ARC-defined "definite" and "probable" stent thrombosis, and the combined incidence of "definite/probable" stent thrombosis. 30 days, 6, 9, 12, 24 and 36 months after index PCI
Secondary Duration of dual antiplatelet therapy Duration of DAPT after index PCI including the reason for interruption and discontinuation. 12, 24 and 36 months after index PCI
Secondary Cerebrovascular accident Neurological disorder that appears rapidly and persists for at least 24 hours, and is attributable to a reduction in the cerebrovascular blood flow due to bleeding or ischemia.
If an AE due to CVA occurs, it is desirable to obtain diagnostic imaging findings constituting evidence or a diagnosis by a specialist.
TIA of which the symptoms disappear within 24 hours is not CVA.
30 days, 6, 9, 12, 24 and 36 months afetr index PCI
Secondary Procedure success The attainment of < 50%, residual stenosis of the target lesion and no in-hospital MACE as reported by the physician. stent implantation until hospital discharge (average 1-5 days)
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A